Evidence map›Paper›PMID 27049928›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2016

Identification and Characterization of CD133(pos) Subpopulation Cells From a Human Laryngeal Cancer Cell Line.

Hai-ou Qiu, Huifang Wang, Na Che, Dong Li, Yong Mao, Qiao Zeng, Rongming Ge

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Application of mPEG-CS-cRGD/Drug delivery · 2023
    Article
  3. Article
  4. Article
  5. Synergy of Dendritic Cell Vaccines and Avasimibe in Treatment of Head and Neck Cancer in Mice.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  6. The Clinical Signification of Claudin-11 Promoter Hypermethylation for Laryngeal Squamous Cell Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hai-ou QiuDepartments of Otolaryngology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Huifang WangDepartments of Nephrology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Na CheDepartments of Otolaryngology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Dong LiDepartments of Clinical Laboratory, Tongji Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Yong MaoDepartments of Otolaryngology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Qiao ZengDepartments of Translational Center for Stem Cell Research, Tongji Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Rongming GeDepartments of Otolaryngology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Tongji Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent research indicates that CD133 are expressed in several kinds of stem cells, among which, its high expression in laryngeal carcinoma has caused wide concern. To further explore efficaciously targeting drugs to laryngeal carcinoma stem cells (CSCs), we transplanted a solid tumor from CSCs into abdominal subcutaneous tissue of nude mice, and then compared the biological characteristics of laryngeal solid tumors with or without cisplatin intervention. MATERIAL/

methodsIn this study, the expression of CD133 was detected in the Hep-2 cell line by flow cytometry. By applying magnetic cell sorting (MACS) technology, we reported the results of purifying CD133-positive cells from a Hep-2 cell line. Cell proliferation, colony formation, and tumor-forming ability were examined in vitro and in vivo to identify the marker of CSCs in Hep-2 cell line.

resultsUpon flow cytometry analysis, CD133 was expressed constantly on 40.12±1.32% in Hep-2 cell line. Cell proliferation and colony formation ability were higher in CD133-positive cells compared to CD133-negative cells, and the in vivo tumorigenesis experiment showed the same results as in vitro assay. The 2 subpopulations cells were both sensitive to DDP, among which, the effect of DPP on proliferation ability and tumor-forming ability of CD133-positive cells was obviously greater than that of CD133-negative cells.

conclusionsAbove all, our study revealed that CD133-positive cells have properties of higher proliferation, colony formation, and tumorigenesis in Hep-2 cell line, indicating that CD133 could be a marker to characterize laryngeal cancer stem cells.

Indexed as

AC133 AntigenAnimalsCell Line, TumorCell ProliferationCell SeparationCisplatinFlow CytometryHumansLaryngeal NeoplasmsMagnetic PhenomenaMaleMice, Inbred BALB CMice, NudeTumor BurdenTumor Stem Cell AssayAC133 AntigenCisplatin

Identifiers

PMID27049928
PMCPMC4825878
OpenAlexW2341687195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.